SI3168218T1 - Kristal, ki vključuje sol L-jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, za uporabo kot zdravilo - Google Patents
Kristal, ki vključuje sol L-jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, za uporabo kot zdraviloInfo
- Publication number
- SI3168218T1 SI3168218T1 SI200231093T SI200231093T SI3168218T1 SI 3168218 T1 SI3168218 T1 SI 3168218T1 SI 200231093 T SI200231093 T SI 200231093T SI 200231093 T SI200231093 T SI 200231093T SI 3168218 T1 SI3168218 T1 SI 3168218T1
- Authority
- SI
- Slovenia
- Prior art keywords
- ylidene
- indol
- carboxamide
- diethylamino
- pyrrole
- Prior art date
Links
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31235301P | 2001-08-15 | 2001-08-15 | |
| EP16196036.4A EP3168218B1 (en) | 2001-08-15 | 2002-08-13 | A crystal comprising an l-malic acid salt of n-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide for use as a medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3168218T1 true SI3168218T1 (sl) | 2019-05-31 |
Family
ID=23211067
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200231093T SI3168218T1 (sl) | 2001-08-15 | 2002-08-13 | Kristal, ki vključuje sol L-jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, za uporabo kot zdravilo |
| SI200231043T SI1419151T1 (sl) | 2001-08-15 | 2002-08-13 | Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200231043T SI1419151T1 (sl) | 2001-08-15 | 2002-08-13 | Kristali, ki vključujejo sol jabolčne kisline N-(2-(dietilamino)etil)-5-((5-fluoro-1,2-dihidro-2-okso-3H-indol-3- iliden)metil)-2,4-dimetil-1H-pirol-3-karboksamida, postopki za njihovo pripravo in sestavki le-teh |
Country Status (42)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3168218T3 (en) | 2001-08-15 | 2019-01-14 | Pharmacia & Upjohn Co Llc | Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE |
| TW200418836A (en) * | 2002-09-10 | 2004-10-01 | Pharmacia Italia Spa | Formulations comprising an indolinone compound |
| MXPA06003661A (es) * | 2003-10-02 | 2006-06-05 | Pharmacia & Upjohn Co Llc | Sales y polimorfos de un compuesto de indolinona sustituido con pirrol. |
| US20060009510A1 (en) * | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
| EP1773811B1 (en) * | 2004-07-22 | 2010-09-08 | Eli Lilly And Company | A crystalline variable hydrate of (s)-6-(4-(2-((3-(9h-carbazol-4-yloxy)-2-hydroxypropyl)amino)-2-methylpropyl)phenoxy)-3-pyridinecarbox amide hemisuccinate salt |
| KR20070119745A (ko) * | 2005-05-12 | 2007-12-20 | 화이자 인코포레이티드 | 수니티닙 말레이트를 사용하는 항암 병행 요법 |
| DE602006008015D1 (de) | 2005-09-19 | 2009-09-03 | Pfizer Prod Inc | Feste salzformen eines pyrrolsubstituierten 2-indolinons |
| US20090004213A1 (en) | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| EP2220072A2 (en) * | 2007-11-21 | 2010-08-25 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| US20100256392A1 (en) * | 2007-11-21 | 2010-10-07 | Teva Pharmaceutical Industries Ltd. | Polymorphs of sunitinib base and processes for preparation thereof |
| WO2009074862A1 (en) * | 2007-12-12 | 2009-06-18 | Medichem S.A. | Polymorphic forms of a 3-pyrrole substituted 2-indolinone |
| EP2090306A1 (en) | 2008-02-13 | 2009-08-19 | Ratiopharm GmbH | Pharmaceutical compositions comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| EP2113248A1 (en) | 2008-04-29 | 2009-11-04 | Ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2-,4-dimethyl-1H-pyrrole-3-carboxamide |
| US20110112164A1 (en) * | 2008-02-21 | 2011-05-12 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
| EP2098521A1 (en) * | 2008-03-06 | 2009-09-09 | Ratiopharm GmbH | Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation |
| PL2274303T3 (pl) * | 2008-03-31 | 2013-03-29 | Teva Pharma | Sposoby otrzymywania sunitynibu i jego soli |
| KR20100135910A (ko) * | 2008-04-16 | 2010-12-27 | 낫코 파마 리미티드 | 수니티닙 염기의 신규한 다형 형태 |
| US8829039B2 (en) | 2008-05-23 | 2014-09-09 | Shanghai Institute Of Pharmaceutical Industry | Dihydroindolinone derivatives |
| US8153678B2 (en) * | 2008-06-13 | 2012-04-10 | Medichem, S.A. | Process for preparing A 3-pyrrole substituted 2-indolinone malate salt |
| EP2138167A1 (en) | 2008-06-24 | 2009-12-30 | ratiopharm GmbH | Pharmaceutical composition comprising N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide |
| WO2009156837A2 (en) * | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
| JP2011527330A (ja) * | 2008-07-10 | 2011-10-27 | ジェネリクス・（ユーケー）・リミテッド | スニチニブリンゴ酸塩の結晶形の調製方法 |
| WO2010010454A2 (en) | 2008-07-24 | 2010-01-28 | Medichem, S.A. | Crystalline forms of a 3-pyrrole substituted 2-indolinone malate salt |
| CA2731605A1 (en) | 2008-07-24 | 2010-01-28 | Teva Pharmaceutical Industries Ltd. | Sunitinib and salts thereof and their polymorphs |
| CN102197034A (zh) * | 2008-08-25 | 2011-09-21 | 基因里克斯(英国)有限公司 | 舒尼替尼的新型多晶型物及其制备方法 |
| CA2734965A1 (en) * | 2008-08-25 | 2010-03-04 | Generics [Uk] Limited | Novel crystalline form and processes for its preparation |
| EP2350056A1 (en) * | 2008-10-10 | 2011-08-03 | Medichem, S.A. | Process for preparing a 3-pyrrole subsituted 2-indolinone malate salt |
| EP2181991A1 (en) * | 2008-10-28 | 2010-05-05 | LEK Pharmaceuticals D.D. | Novel salts of sunitinib |
| EP2186809A1 (en) * | 2008-11-13 | 2010-05-19 | LEK Pharmaceuticals D.D. | New crystal form of sunitinib malate |
| WO2010076805A2 (en) | 2009-01-02 | 2010-07-08 | Hetero Research Foundation | Novel polymorphs of sunitinib malate |
| EA038195B1 (ru) | 2009-01-16 | 2021-07-22 | Экселиксис, Инк. | Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени |
| EP2255792A1 (en) | 2009-05-20 | 2010-12-01 | Ratiopharm GmbH | Pharmaceutical compositions for N-[2-(Diethylamino)ethyl]5-[(fluoro-1,2-dihydro-2-oxo-3H-indole-3-ylidene) methyl]-2,4-dimenthyl-1H-pyrrole-3-carboxamide |
| WO2011004200A1 (en) | 2009-07-10 | 2011-01-13 | Generics [Uk] Limited | Novel pyrrole derivatives |
| WO2011033472A1 (en) | 2009-09-16 | 2011-03-24 | Ranbaxy Laboratories Limited | Salts of sunitinib |
| WO2011058521A2 (en) * | 2009-11-12 | 2011-05-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form i of l-malic acid salt of sunitinib |
| US8916716B2 (en) | 2009-11-19 | 2014-12-23 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form II of L-malic acid salt of sunitinib |
| EP2528913A1 (en) | 2010-01-29 | 2012-12-05 | Ranbaxy Laboratories Limited | Crystalline forms of l-malic acid salt of sunitinib |
| WO2011100325A2 (en) | 2010-02-09 | 2011-08-18 | Sicor Inc. | Polymorphs of sunitinib salts |
| WO2011104555A2 (en) | 2010-02-25 | 2011-09-01 | Generics [Uk] Limited | Novel process |
| EP2542550A1 (en) | 2010-03-04 | 2013-01-09 | Ranbaxy Laboratories Limited | Process for the direct preparation of malic acid salt of sunitinib |
| US20160185760A1 (en) | 2010-03-18 | 2016-06-30 | Ranbaxy Laboratories Limited | Process for the preparation of malic acid salt of sunitinib |
| WO2011128699A2 (en) | 2010-04-16 | 2011-10-20 | Generics [Uk] Limited | Novel process |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| EP2699598B1 (en) | 2011-04-19 | 2019-03-06 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
| ES2709110T3 (es) | 2012-03-23 | 2019-04-15 | Laurus Labs Ltd | Un proceso mejorado para la preparación de sunitinib y sus sales de adición de ácido |
| PL399027A1 (pl) | 2012-04-27 | 2013-10-28 | Instytut Farmaceutyczny | Sposób otrzymywania N-[2-(dietylamino)etylo]-5-formylo-2,4-dimetylo-1H-pirolo-3-karboksyamidu o wysokiej czystosci i jego zastosowanie do wytwarzania sunitynibu |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| US9604968B2 (en) * | 2013-10-18 | 2017-03-28 | Sun Pharmaceutical Industries Limited | Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation |
| US9278955B2 (en) | 2013-10-18 | 2016-03-08 | Sun Pharmaceutical Industries Limited | Ascorbic acid salt of sunitinib |
| HUE043042T2 (hu) | 2013-11-01 | 2019-07-29 | Pfizer | Vektorok prosztatához kapcsolódó antigének expressziójára |
| CN104693187A (zh) * | 2013-12-10 | 2015-06-10 | 安杰世纪生物科技（北京）有限公司 | 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法 |
| CN104744442B (zh) * | 2013-12-25 | 2019-05-28 | 江苏豪森药业集团有限公司 | 苹果酸舒尼替尼的制备方法 |
| RU2567535C1 (ru) * | 2014-10-01 | 2015-11-10 | Олег Ростиславович Михайлов | КРИСТАЛЛИЧЕСКАЯ ε-МОДИФИКАЦИЯ N-[2-(ДИЭТИЛАМИНО)ЭТИЛ]-5-[(Z)-(5-ФТОР-1,2-ДИГИДРО-2-ОКСО-3Н-ИНДОЛ-3-ИЛИДЕН)МЕТИЛ]-2,4-ДИМЕТИЛ-1Н-ПИРРОЛ-3-КАРБОКСАМИД МАЛАТА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ |
| CN105712979A (zh) * | 2014-12-05 | 2016-06-29 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种苹果酸舒尼替尼晶型ⅰ的制备方法 |
| EP3539536A1 (en) | 2018-03-15 | 2019-09-18 | MH10 Spolka z ograniczona odpowiedzialnoscia | A pharmaceutical composition of sunitinib or its salt thereof in its polymorphic form i |
| AU2020257415A1 (en) * | 2019-04-18 | 2021-11-11 | Meter Health, Inc. | Methods and compositions for treating respiratory arrhythmias |
| EP3958845A1 (en) | 2019-04-25 | 2022-03-02 | Synthon B.V. | Pharmaceutical composition comprising amorphous sunitinib |
| JP7633786B2 (ja) * | 2020-09-18 | 2025-02-20 | 日本化薬株式会社 | スニチニブリンゴ酸塩を有効成分とする医薬錠剤 |
| KR20240025990A (ko) | 2022-08-19 | 2024-02-27 | 주식회사 스카이테라퓨틱스 | 무정형 수니티닙, 그 제조방법 및 이를 포함한 의약 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2091562C (en) | 1990-10-15 | 2001-03-27 | John Eugene Macor | Indole derivatives useful in psychotherapeutics |
| IL100091A (en) * | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| ES2116411T3 (es) | 1992-06-05 | 1998-07-16 | Merck Sharp & Dohme | La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia |
| WO1994020505A1 (en) | 1993-03-12 | 1994-09-15 | The Upjohn Company | Crystalline ceftiofur free acid |
| US5665878A (en) * | 1994-08-31 | 1997-09-09 | Eli Lilly And Company | Stereoselective process for producing dihydro-2,3-benzodiazepine derivatives |
| DE19503966C2 (de) * | 1995-02-07 | 1998-07-02 | Mack Chem Pharm | Kristallmodifikation von 2,4-Diamino-6-hydroxymethylpteridin-Hydrobromid, Verfahren zu dessen Herstellung und dessen Verwendung |
| US5597663A (en) * | 1995-05-30 | 1997-01-28 | Motorola, Inc. | Low temperature molten lithium salt electrolytes for electrochemical cells |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| US5673451A (en) * | 1995-07-06 | 1997-10-07 | Moore; James R. | Instructional toothbrush |
| US20020038021A1 (en) * | 1995-12-11 | 2002-03-28 | Barton Kathleen P. | Eplerenone crystalline form exhibiting enhanced dissolution rate |
| US20020045746A1 (en) * | 1995-12-11 | 2002-04-18 | Barton Kathleen P. | Eplerenone crystalline form |
| US6066647A (en) * | 1996-07-29 | 2000-05-23 | Pfizer Inc. | Zwitterionic forms of trovafloxacin |
| SI9720059B (sl) | 1996-08-14 | 2011-11-30 | Searle & Co | Kristalinična oblika 4-/5-metil-3-fenilizoksazol-4-il/benzensulfonamida |
| KR100530601B1 (ko) * | 1996-12-25 | 2005-11-23 | 니폰 가야꾸 가부시끼가이샤 | 시스플라틴 미분말 및 그의 제조방법 |
| US5777185A (en) * | 1997-09-09 | 1998-07-07 | Laroche Industries Inc. | Production of organic fluorine compounds |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| US6012678A (en) * | 1998-01-26 | 2000-01-11 | The Boeing Company | Galley vacuum waste disposal system |
| SK287928B6 (sk) | 1998-06-19 | 2012-04-03 | Teijin Pharma Limited | Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4- methyl-5-thiazole-carboxylic acid and processes for the preparation thereof |
| BR9916327A (pt) * | 1998-12-17 | 2001-09-18 | Hoffmann La Roche | Oxindóis de 4-alquenila (e alquinila) como inibidores de cinases dependentes de ciclina, em particular, cdk2 |
| US6239141B1 (en) | 1999-06-04 | 2001-05-29 | Pfizer Inc. | Trovafloxacin oral suspensions |
| DK1233943T3 (da) * | 1999-11-24 | 2011-08-15 | Sugen Inc | Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander |
| AR034118A1 (es) | 2000-02-15 | 2004-02-04 | Sugen Inc | Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis |
| US6316672B1 (en) * | 2001-01-31 | 2001-11-13 | Grayson Walker Stowell | Form a of fluoxetine hydrochloride |
| DK3168218T3 (en) | 2001-08-15 | 2019-01-14 | Pharmacia & Upjohn Co Llc | Crystalline comprising an L-malic acid salt of N- [2- (DIETHYLAMINO) ETHYL] -5 - [(5-FLUOR-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE) METHYL] -2,4 -DIMETHYL-1H-PYRROL-3-CARBOXAMIDE FOR USE AS A MEDICINE |
| US20110112164A1 (en) | 2008-02-21 | 2011-05-12 | Generics (Uk) Limited | Novel polymorphs and processes for their preparation |
| WO2009156837A2 (en) | 2008-06-26 | 2009-12-30 | Medichem, S.A. | Amorphous form of a 3-pyrrole substituted 2-indolinone malate salt |
-
2002
- 2002-08-13 DK DK16196036.4T patent/DK3168218T3/en active
- 2002-08-13 HR HR20040112A patent/HRP20040112B1/xx not_active IP Right Cessation
- 2002-08-13 CA CA002455050A patent/CA2455050C/en not_active Expired - Lifetime
- 2002-08-13 UA UA2004021084A patent/UA76483C2/uk unknown
- 2002-08-13 AU AU2002324684A patent/AU2002324684B2/en not_active Expired
- 2002-08-13 SK SK90-2004A patent/SK902004A3/sk unknown
- 2002-08-13 EA EA200400183A patent/EA006445B9/ru unknown
- 2002-08-13 DK DK02759342.5T patent/DK1419151T3/da active
- 2002-08-13 RS YU10304A patent/RS53251B/sr unknown
- 2002-08-13 JP JP2003521228A patent/JP4159988B2/ja not_active Expired - Lifetime
- 2002-08-13 MX MXPA04001452A patent/MXPA04001452A/es active IP Right Grant
- 2002-08-13 PT PT2759342T patent/PT1419151E/pt unknown
- 2002-08-13 NZ NZ531232A patent/NZ531232A/en not_active IP Right Cessation
- 2002-08-13 EP EP16196036.4A patent/EP3168218B1/en not_active Expired - Lifetime
- 2002-08-13 ES ES16196036T patent/ES2705063T3/es not_active Expired - Lifetime
- 2002-08-13 ES ES02759342.5T patent/ES2453164T3/es not_active Expired - Lifetime
- 2002-08-13 ME MEP-2008-520A patent/ME00414B/me unknown
- 2002-08-13 EP EP02759342.5A patent/EP1419151B1/en not_active Expired - Lifetime
- 2002-08-13 HU HU0700036A patent/HU229206B1/hu unknown
- 2002-08-13 TR TR2019/00509T patent/TR201900509T4/tr unknown
- 2002-08-13 IL IL16009702A patent/IL160097A0/xx active IP Right Grant
- 2002-08-13 ES ES11156767.3T patent/ES2623094T3/es not_active Expired - Lifetime
- 2002-08-13 CZ CZ2004196A patent/CZ2004196A3/cs unknown
- 2002-08-13 OA OA1200400044A patent/OA12650A/en unknown
- 2002-08-13 PT PT16196036T patent/PT3168218T/pt unknown
- 2002-08-13 EP EP11156767.3A patent/EP2332934B1/en not_active Expired - Lifetime
- 2002-08-13 SI SI200231093T patent/SI3168218T1/sl unknown
- 2002-08-13 WO PCT/US2002/025649 patent/WO2003016305A1/en not_active Ceased
- 2002-08-13 GE GE5446A patent/GEP20063777B/en unknown
- 2002-08-13 KR KR1020047002173A patent/KR100639281B1/ko not_active Expired - Lifetime
- 2002-08-13 CN CNB02815892XA patent/CN100439360C/zh not_active Ceased
- 2002-08-13 PL PL368317A patent/PL216524B1/pl unknown
- 2002-08-13 BR BR0211612-0A patent/BR0211612A/pt not_active Application Discontinuation
- 2002-08-13 SI SI200231043T patent/SI1419151T1/sl unknown
- 2002-08-13 CN CNB2005101286242A patent/CN100364991C/zh not_active Expired - Lifetime
- 2002-08-13 AP APAP/P/2004/002976A patent/AP1660A/en active
- 2002-08-13 US US10/218,985 patent/US20030069298A1/en not_active Abandoned
- 2002-08-15 MY MYPI20023032A patent/MY139383A/en unknown
- 2002-08-15 AR ARP020103088A patent/AR036261A1/es unknown
- 2002-08-15 TW TW091118419A patent/TWI269796B/zh active
-
2004
- 2004-01-16 CO CO04002781A patent/CO5550431A2/es not_active Application Discontinuation
- 2004-01-28 ZA ZA2004/00706A patent/ZA200400706B/en unknown
- 2004-01-29 BG BG108553A patent/BG108553A/bg unknown
- 2004-02-10 EC EC2004004975A patent/ECSP044975A/es unknown
- 2004-02-10 IS IS7147A patent/IS7147A/is unknown
- 2004-02-11 MA MA27522A patent/MA27058A1/fr unknown
- 2004-02-12 CU CU20040029A patent/CU23713B7/es active IP Right Grant
- 2004-02-12 TN TNP2004000028A patent/TNSN04028A1/fr unknown
- 2004-03-12 NO NO20041054A patent/NO326508B1/no not_active IP Right Cessation
-
2007
- 2007-04-26 US US11/740,644 patent/US7435832B2/en not_active Expired - Lifetime
-
2018
- 2018-12-12 CY CY20181101336T patent/CY1121552T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3168218T (pt) | Um cristal compreendendo um sal de ácido l-málico de n-[2- (dietilamino)etil]-5-[(5-fluoro-1,2-dihidro-2-oxo-3h-indol- 3-ilideno)metil]-2,4-dimetil-1h-pirrol-3-carboxamida para utilização como um medicamento | |
| NO2019005I1 (no) | N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-1,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-1H-pyrrol-3-karboksamid (sunitinib), samt farmasøytisk akseptable salter | |
| DK1353917T3 (da) | Ny fremgangsmåde til syntesen af 5-(4-fluorphenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrol-3-carboxylsyre phenylamid | |
| IL180147A0 (en) | N - (1 - (1 - benzyl - 4 - phenyl - 1h-imidazol - 2 - yl) - 2,2 - dymethylpropyl) benzamide derivatives and related compounds as kinesin spidle protein (ksp) inhibitors for the treatment of cancer | |
| MXPA05007609A (es) | Antagonista de un receptor sensible al calcio. | |
| WO2004013100A3 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
| PL2247585T3 (pl) | Krystaliczne postacie N-[2-(dietyloamino)etylo]-5-[(5-fluoro-1,2-dihydro-2-okso-3H-indol-3-ilideno)metylo]-2,4-dimetylo-1H-pirolo-3-karboksamidu i sposoby ich otrzymywania | |
| EA200600381A1 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение в качестве лекарственного средства | |
| NZ592258A (en) | Pesticidal (hetero) arylpyrrolidines | |
| RU2007121850A (ru) | Производные фосфонооксихиназолина и их фармацевтическое применение | |
| NO20031266L (no) | Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon | |
| MXPA05010521A (es) | Inhibidores de cinasa de amida de bifenilcarboxilica p38. | |
| ZA200101821B (en) | Use of heteroaryl substituted n-(indole-2-carbonyl-) amides for treatment of infection. | |
| IL181009A0 (en) | N-(phenyl-oxazol-4-ylmethoxymethyl)-cyclohexyl-succinic acid amide derivatives and related compounds which are used as ppar-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes | |
| ATE534375T1 (de) | Pharmazeutische zusammensetzung mit n-ä2- (diethylamino)ethylü-5-ä(5-fluoro-1,2- dihydro-2- oxo-3h-indol-3-yliden)methylü-2,4-dimethyl-1h- pyrrol-3-carbonsäureamid | |
| EP1716134A4 (en) | HETEROCYCLIC AMINO MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY | |
| WO2006107062A3 (en) | Benzimidazole derivative and use as angiotensin ii antagonist | |
| PL375415A1 (en) | Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide | |
| FR2847458B1 (fr) | Dispositif de stabilisation des prothese totales articulaires sphero-spheriques | |
| TWI320407B (en) | Method for preparing n-(trifluoromethyl substituted phenyl) maleimides | |
| CY1115143T1 (el) | Κρυσταλλοι που περιλαμβανουν μηλικο αλας του ν-[2-(διαιθυλαμινο)αιθυλο]-5-[(5-φθορο-1,2-διϋδρο-2-οξο-3η-ινδολ-3-ιλιδενο)μεθυλο]-2,4-διμεθυλο-1η-πυρρολο-3-καρβοξαμιδιου, διεργασιες παρασκευης αυτων και συνθεσεις αυτων | |
| AU2002356352A1 (en) | Use of 5-chloro-4-(3-(n-(2-(3,4-dimethoxy-phenyl)-ethyl)-n-methylamino)-propylamino)-3-(2h)-pyridazinone as metabolic modulator | |
| PE20041058A1 (es) | Derivados de fenilalanina como inhibidores de la dipeptidilpeptidasa | |
| AU2003220820A1 (en) | Remedies for pemphigus containing cd40l antagonist as the active ingredient |